Tango Therapeutics, Inc.
Tango Therapeutics, Inc. (TNGX): 19 pipeline candidates · 3 upcoming catalysts · ~25 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
25.3 months
D/E 0.11 · 0% dilution
Lead: Phase 3
19 candidates
3 upcoming, next in ~1170d
0 buys · 15 sells (180d)
A transparent, data-derived signal for Tango Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.3B
Cash
$160.0M
Quarterly Burn
$44.4M
Runway
25.3 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (19 candidates)
| Drug | Phase |
|---|---|
| 5-FU | Phase 3 |
| ASP2138 | Phase 1 |
| Autogene cevumeran | Phase 2 |
| First-Line Systemic Therapy | — |
| Folfirinox | Phase 3 |
| Leucovorin | Phase 3 |
| M0324 | Phase 1 |
| mFOLFIRINOX | Phase 3 |
| mFOLFIRINOX infusion | Phase 3 |
| Ramucirumab | Phase 1 |
Showing 10 of 19 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
190
Total value held
$3.05B
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 13,300,620 | $278.2M |
| adage capital partners gp, l.l.c. | 12,809,485 | $268.0M |
| vanguard capital management llc | 10,322,862 | $216.0M |
| fmr llc | 9,905,919 | $207.2M |
| farallon capital management llc | 9,097,411 | $190.3M |
| blackrock, inc. | 8,748,045 | $183.0M |
| siren, l.l.c. | 5,657,105 | $118.3M |
| goldman sachs group inc | 5,076,392 | $106.2M |
| janus henderson group plc | 4,789,944 | $100.1M |
| state street corp | 4,651,894 | $97.3M |
Showing top 10 of 190 institutional holders of Tango Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Tango Therapeutics, Inc.'s pipeline?
Tango Therapeutics, Inc. (TNGX) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Tango Therapeutics, Inc.'s lead drug candidate?
Tango Therapeutics, Inc.'s most advanced tracked candidate is 5-FU (Phase 3) for Pancreatic Ductal Adenocarcinoma.
What is Tango Therapeutics, Inc.'s next catalyst?
Tango Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of A" — expected August 31, 2029.
What is Tango Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Tango Therapeutics, Inc. has approximately 25.3 months of cash runway.
What is Tango Therapeutics, Inc.'s market capitalization?
Tango Therapeutics, Inc.'s market capitalization is approximately $5.3B.
Get the full picture on Tango Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.